Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: Results from the ESCALATOR trial

Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Diana Rofail, Jean François Baladi, Dany Habr, Ulrike Kriemler-Krahn, Amal El-Beshlawy

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Patient-reported outcomes of once-daily oral deferasirox (Exjade®) in iron-overloaded patients with β-thalassemia not achieving successful chelation with prior deferoxamine and/or deferiprone were investigated in a prospective, open-label, 1-year, multicenter study in the Middle East (ESCALATOR). The initial dose of deferasirox was 20 mg/kg/day, with subsequent dose adjustments. At baseline and the end of study (EOS), patients (n = 237) completed a 5-point rating scale for treatment satisfaction and convenience, and recorded time lost to treatment. At EOS, 90.7% of patients were 'satisfied'/'very satisfied' with their iron chelation therapy (ICT) versus 23.2% at baseline. 92.8% (EOS) versus 21.5% (baseline) of patients considered their therapy to be 'convenient'/'very convenient'. Time lost to therapy for daily activities was substantially reduced (3.2 ± 8.6 [mean ± SD; EOS] vs. 30.1 ± 44.2 [baseline] h/month). Patients reported greater satisfaction and convenience, and lower impact on daily activities, with deferasirox than with previous ICT. This may help improve adherence to lifelong ICT in iron-overloaded β-thalassemia patients.

Original languageEnglish
Pages (from-to)220-225
Number of pages6
JournalActa Haematologica
Volume123
Issue number4
DOIs
Publication statusPublished - May 2010

Fingerprint

Thalassemia
Iron
Chelation Therapy
Therapeutics
Social Adjustment
Deferoxamine
Middle East
Multicenter Studies
deferasirox

Keywords

  • β-Thalassemia
  • Convenience
  • Deferasirox
  • Iron chelation therapy
  • Iron overload

ASJC Scopus subject areas

  • Hematology

Cite this

Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia : Results from the ESCALATOR trial. / Taher, Ali; Al Jefri, Abdullah; Elalfy, Mohsen Saleh; Al Zir, Kusai; Daar, Shahina; Rofail, Diana; Baladi, Jean François; Habr, Dany; Kriemler-Krahn, Ulrike; El-Beshlawy, Amal.

In: Acta Haematologica, Vol. 123, No. 4, 05.2010, p. 220-225.

Research output: Contribution to journalArticle

Taher, A, Al Jefri, A, Elalfy, MS, Al Zir, K, Daar, S, Rofail, D, Baladi, JF, Habr, D, Kriemler-Krahn, U & El-Beshlawy, A 2010, 'Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: Results from the ESCALATOR trial', Acta Haematologica, vol. 123, no. 4, pp. 220-225. https://doi.org/10.1159/000313447
Taher, Ali ; Al Jefri, Abdullah ; Elalfy, Mohsen Saleh ; Al Zir, Kusai ; Daar, Shahina ; Rofail, Diana ; Baladi, Jean François ; Habr, Dany ; Kriemler-Krahn, Ulrike ; El-Beshlawy, Amal. / Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia : Results from the ESCALATOR trial. In: Acta Haematologica. 2010 ; Vol. 123, No. 4. pp. 220-225.
@article{d74b4141a58f412792c7e47592d6957c,
title = "Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: Results from the ESCALATOR trial",
abstract = "Patient-reported outcomes of once-daily oral deferasirox (Exjade{\circledR}) in iron-overloaded patients with β-thalassemia not achieving successful chelation with prior deferoxamine and/or deferiprone were investigated in a prospective, open-label, 1-year, multicenter study in the Middle East (ESCALATOR). The initial dose of deferasirox was 20 mg/kg/day, with subsequent dose adjustments. At baseline and the end of study (EOS), patients (n = 237) completed a 5-point rating scale for treatment satisfaction and convenience, and recorded time lost to treatment. At EOS, 90.7{\%} of patients were 'satisfied'/'very satisfied' with their iron chelation therapy (ICT) versus 23.2{\%} at baseline. 92.8{\%} (EOS) versus 21.5{\%} (baseline) of patients considered their therapy to be 'convenient'/'very convenient'. Time lost to therapy for daily activities was substantially reduced (3.2 ± 8.6 [mean ± SD; EOS] vs. 30.1 ± 44.2 [baseline] h/month). Patients reported greater satisfaction and convenience, and lower impact on daily activities, with deferasirox than with previous ICT. This may help improve adherence to lifelong ICT in iron-overloaded β-thalassemia patients.",
keywords = "β-Thalassemia, Convenience, Deferasirox, Iron chelation therapy, Iron overload",
author = "Ali Taher and {Al Jefri}, Abdullah and Elalfy, {Mohsen Saleh} and {Al Zir}, Kusai and Shahina Daar and Diana Rofail and Baladi, {Jean Fran{\cc}ois} and Dany Habr and Ulrike Kriemler-Krahn and Amal El-Beshlawy",
year = "2010",
month = "5",
doi = "10.1159/000313447",
language = "English",
volume = "123",
pages = "220--225",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia

T2 - Results from the ESCALATOR trial

AU - Taher, Ali

AU - Al Jefri, Abdullah

AU - Elalfy, Mohsen Saleh

AU - Al Zir, Kusai

AU - Daar, Shahina

AU - Rofail, Diana

AU - Baladi, Jean François

AU - Habr, Dany

AU - Kriemler-Krahn, Ulrike

AU - El-Beshlawy, Amal

PY - 2010/5

Y1 - 2010/5

N2 - Patient-reported outcomes of once-daily oral deferasirox (Exjade®) in iron-overloaded patients with β-thalassemia not achieving successful chelation with prior deferoxamine and/or deferiprone were investigated in a prospective, open-label, 1-year, multicenter study in the Middle East (ESCALATOR). The initial dose of deferasirox was 20 mg/kg/day, with subsequent dose adjustments. At baseline and the end of study (EOS), patients (n = 237) completed a 5-point rating scale for treatment satisfaction and convenience, and recorded time lost to treatment. At EOS, 90.7% of patients were 'satisfied'/'very satisfied' with their iron chelation therapy (ICT) versus 23.2% at baseline. 92.8% (EOS) versus 21.5% (baseline) of patients considered their therapy to be 'convenient'/'very convenient'. Time lost to therapy for daily activities was substantially reduced (3.2 ± 8.6 [mean ± SD; EOS] vs. 30.1 ± 44.2 [baseline] h/month). Patients reported greater satisfaction and convenience, and lower impact on daily activities, with deferasirox than with previous ICT. This may help improve adherence to lifelong ICT in iron-overloaded β-thalassemia patients.

AB - Patient-reported outcomes of once-daily oral deferasirox (Exjade®) in iron-overloaded patients with β-thalassemia not achieving successful chelation with prior deferoxamine and/or deferiprone were investigated in a prospective, open-label, 1-year, multicenter study in the Middle East (ESCALATOR). The initial dose of deferasirox was 20 mg/kg/day, with subsequent dose adjustments. At baseline and the end of study (EOS), patients (n = 237) completed a 5-point rating scale for treatment satisfaction and convenience, and recorded time lost to treatment. At EOS, 90.7% of patients were 'satisfied'/'very satisfied' with their iron chelation therapy (ICT) versus 23.2% at baseline. 92.8% (EOS) versus 21.5% (baseline) of patients considered their therapy to be 'convenient'/'very convenient'. Time lost to therapy for daily activities was substantially reduced (3.2 ± 8.6 [mean ± SD; EOS] vs. 30.1 ± 44.2 [baseline] h/month). Patients reported greater satisfaction and convenience, and lower impact on daily activities, with deferasirox than with previous ICT. This may help improve adherence to lifelong ICT in iron-overloaded β-thalassemia patients.

KW - β-Thalassemia

KW - Convenience

KW - Deferasirox

KW - Iron chelation therapy

KW - Iron overload

UR - http://www.scopus.com/inward/record.url?scp=77951240325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951240325&partnerID=8YFLogxK

U2 - 10.1159/000313447

DO - 10.1159/000313447

M3 - Article

C2 - 20424435

AN - SCOPUS:77951240325

VL - 123

SP - 220

EP - 225

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 4

ER -